Pereira, Ana RitaCalé, RitaFerreira, FilipaPereira, Helder2025-07-022025-07-022022BMJ Case Rep. 2022 Apr 4;15(4):e247318http://hdl.handle.net/10400.5/101974© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.Balloon pulmonary angioplasty (BPA) is an emerging treatment for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or residual/recurrent pulmonary hypertension after pulmonary thromboendarterectomy. We report two patients with inoperable and severe CTEPH who were submitted to the BPA programme after optimised treatment with long-term oxygen therapy (LTOT) and pulmonary vasodilator drugs, including prostacyclin analogues. They experienced a significant improvement in exercise capacity, oxygenation, right ventricular function and pulmonary haemodynamics. This improvement allowed withdrawal from LTOT and prostacyclin analogues therapies and, consequently, improved patients' quality of life and reduced future health-related costs. The reported clinical cases intend to highlight the effectiveness of BPA in patients with inoperable CTEPH for whom the only available therapy was, until recently, the pulmonary vasodilator drugs.engInterventional cardiologyInterventional radiologyPulmonary embolismPulmonary hypertensionjournal article10.1136/bcr-2021-2473181757-790X